Related Experiment Videos
SKIN PIGMENTATION AND CORNEAL AND LENS OPACITIES WITH PROLONGED CHLORPROMAZINE THERAPY
Canadian Medical Association Journal
|March 14, 1964
Summary
Prolonged, high-dose chlorpromazine therapy in women can cause skin pigmentation and ocular issues like corneal opacity and cataracts. These previously undescribed complications highlight potential risks of long-term antipsychotic use.
Area of Science:
- Dermatology
- Ophthalmology
- Pharmacology
Background:
- Chlorpromazine is a widely used antipsychotic medication.
- Long-term use may be associated with adverse effects.
- Ocular and dermatologic side effects are not well-documented.
Purpose of the Study:
- To describe previously unrecognized ocular and dermatologic complications associated with prolonged chlorpromazine therapy.
- To characterize the clinical and histological features of these adverse events.
Main Methods:
- Observational study of 70 patients experiencing complications.
- Analysis of patient demographics, dosage, duration of therapy, and clinical presentation.
- Histological examination of skin biopsies.
Main Results:
- Complications occurred in women receiving high-dose chlorpromazine (500-1500 mg/day) for 3-5 years.
- Skin manifestations included purplish pigmentation on exposed areas.
- Ocular findings included corneal and lens opacities, with stellate cataracts.
Conclusions:
- Prolonged, high-dose chlorpromazine therapy can lead to distinct ocular and dermatologic complications.
- These findings underscore the importance of monitoring patients on long-term chlorpromazine treatment.
- Further research is needed to elucidate the mechanisms and prevalence of these side effects.